Drug
225Ac-J591
225Ac-J591 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_1
3
75%
Ph early_phase_1
1
25%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
3(75.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (25.0%)
Phase 13 (75.0%)
Trials by Status
completed250%
active_not_recruiting125%
recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_1
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04946370
active_not_recruitingphase_1
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04886986
completedearly_phase_1
Re-treatment 225Ac-J591 for mCRPC
NCT04576871
completedphase_1
Phase I Trial of 225Ac-J591 in Patients With mCRPC
NCT03276572
Clinical Trials (4)
Showing 4 of 4 trials
NCT04946370Phase 1
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04886986Phase 1
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04576871Early Phase 1
Re-treatment 225Ac-J591 for mCRPC
NCT03276572Phase 1
Phase I Trial of 225Ac-J591 in Patients With mCRPC
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4